touchLearning Activities
Education, Conference Coverage and Articles
The phase 3 FUSION trial has met its primary endpoint, with the RNA-targeted therapy ulefnersen demonstrating a significant benefit across a combined measure of function and survival in people with fused in sarcoma-associated amyotrophic lateral sclerosis. Ulefnersen, an investigational antisense oligonucleotide ...
Prof. Hideo Yamanouchi discusses the lifelong impact of Dravet syndrome, the importance of adaptive functioning and genetic diagnosis, and how emerging targeted therapies could reshape treatment goals beyond seizure reduction. Dravet syndrome is increasingly understood as a lifelong genetic neurodevelopmental ...
Explore the National Multiple Sclerosis Society’s new interactive eLearning program, designed to help clinicians understand and apply the 2024 McDonald Criteria in clinical practice The 2024 revisions to the McDonald Criteria represent a substantial evolution in the diagnosis of multiple sclerosis (...
Monthly migraine days remain a central endpoint in migraine trials and clinical practice, but do they capture what matters most to people living with migraine? At the Migraine Trust International Symposium 2026, touchNEUROLOGY spoke with Prof. Stewart J. Tepper about interictal ...
From gene-targeted approaches in Dravet syndrome to positive phase 3 data in focal and generalized seizures, selected presentations at the 16th European Epilepsy Congress highlighted a rapidly evolving epilepsy treatment landscape. Beyond reducing seizure frequency, several studies also explored whether emerging ...
Practical strategies to improve migraine recognition, optimize acute treatment, and support more consistent, individualized care in primary-care settings Migraine is a common and disabling neurological disorder that is frequently managed in primary care. However, gaps in recognition, diagnosis, and acute ...
The Parkinson’s Companion is a free app developed with people living with Parkinson’s and international clinical experts. The app aims to bring a more structured, holistic approach to consultations, combining symptom awareness, medication-related considerations, and lifestyle support. Parkinson’...
Phase 2 LiBBY study highlights the potential of cannabinoid therapy to improve agitation and quality of life in hospice-eligible patients with dementia. At the Alzheimer's Association International Conference (AAIC) 2026, Dr Jacobo Mintzer (Department of Psychiatry and Behavioral Sciences, Medical University of ...
How advances in molecular understanding are shaping Parkinson's disease classification, patient stratification, and the future of personalized care Parkinson’s disease has historically been diagnosed and classified primarily according to clinical features. However, advances in genetics, molecular biomarkers, and our ...
Prof. Kenneth Gorson discusses the unmet need in Guillain–Barré syndrome, the phase 3 GBS-02 trial data evaluating tanruprubart, and how complement inhibition could improve recovery while reducing the long-term healthcare burden of this disabling disease. [touchplayvideo video_id="nt33qaui86"] &...
Highlights from the European Academy of Neurology (EAN) 2026 Congress included new phase 3 data in ocular myasthenia gravis, emerging migraine treatments, longer-term results in multiple sclerosis, and advances in deep brain stimulation for Parkinson’s disease. The 12th Congress of the ...
Leading Alzheimer's disease experts share the therapeutic and research developments they believe had the greatest potential to transform diagnosis, treatment and prevention at the Alzheimer's Association International Conference (AAIC) 2026. The Alzheimer's Association International Conference (AAIC) 2026 showcased advances across the Alzheimer's ...
Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer's disease therapies and advancing our understanding of neuroinflammation. https://touchmedicalmedia-1.wistia.
Prof. Arcadi Navarro discusses BBRC's largest-ever presence at AAIC, the growing role of biomarkers and personalized risk prediction, and why prevention is becoming the future of Alzheimer's disease research. Introduction We spoke with Prof. Arcadi Navarro, Professor of Genetics and ...
Dr Reisa Sperling discusses the rationale for targeting preclinical Alzheimer's disease, the latest long-term data from the Brainshuttle AD programme evaluating trontinemab, and how the PrevenTRON study could help shift Alzheimer's disease treatment towards prevention. We spoke with Dr Reisa ...
Dr Klaus Dugi discusses the first-in-human data for VNA-318, the rationale for targeting cellular energy metabolism in Alzheimer's disease, and how improving mitochondrial function could offer both symptomatic and disease-modifying benefits. We spoke with Klaus Dugi, Chief Executive Officer of ...
Prof. John-Paul Taylor discusses the phase 2b RewinD-LB findings, lessons learned from the neflamapimod programme, and the next steps towards precision medicine in dementia with Lewy bodies We spoke with Prof. John-Paul Taylor, Newcastle University, Newcastle upon Tyne, UK, at ...
touchNEUROLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
